Adaptimmune Therapeutics

About Adaptimmune Therapeutics

Adaptimmune Therapeutics (NASDAQ:ADAP) focuses on the development of novel cancer immunotherapy products. Its main efforts are in spearheading the engineering of specific T-cell receptors (TCRs) for the treatment of cancer. Adaptimmune seeks to harness the power of the body's own immune system to target and destroy cancer cells by enhancing the natural ability of T-cells to fight the disease. With a pipeline of projects in various stages of development, the company aims to deliver innovative therapies for people with cancer, advancing treatments beyond current options. Their objective is to provide new, life-changing options for patients battling cancer, targeting a range of solid tumors and hematologic cancers.

What is Adaptimmune Therapeutics known for?

Snapshot

2008

Year founded

491

Employees

Abingdon, United Kingdom

Head office

Loading Map...

Operations

All Locations

United Kingdom of Great Britain and Northern Ireland

Products and/or services of Adaptimmune Therapeutics

SPEAR T-cell therapy platform, targeting cancer by engineering T-cells to recognize and attack tumors.
ADP-A2M4 for synovial sarcoma and MRCLS, a precision T-cell therapy.
ADP-A2M4CD8, an enhanced T-cell therapy targeting MAGE-A4 positive tumors with improved potency.
T-cell receptor (TCR) library, providing a diverse range of TCRs for rapid development of targeted therapies.
ADP-A2AFP, a T-cell therapy aimed at treating liver cancer by targeting AFP.
Next-generation T-cell therapies, ongoing research into dual-targeting TCRs for more complex tumor types.